ALPINE IMMUNE SCIENCES INC's ticker is ALPN and the CUSIP is 02083G100. A total of 57 filers reported holding ALPINE IMMUNE SCIENCES INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,182,244 | +265.8% | 190,589 | +228.4% | 0.01% | +500.0% |
| Q2 2023 | $596,528 | +277.5% | 58,028 | +164.7% | 0.00% | 0.0% |
| Q3 2022 | $158,000 | -7.1% | 21,924 | +9.5% | 0.00% | 0.0% |
| Q2 2022 | $170,000 | -60.3% | 20,030 | -58.0% | 0.00% | 0.0% |
| Q1 2022 | $428,000 | -61.2% | 47,708 | -40.1% | 0.00% | -50.0% |
| Q4 2021 | $1,104,000 | +164.1% | 79,682 | +103.2% | 0.00% | +100.0% |
| Q3 2021 | $418,000 | +175.0% | 39,218 | +131.9% | 0.00% | – |
| Q2 2021 | $152,000 | -86.6% | 16,914 | -84.2% | 0.00% | -100.0% |
| Q1 2021 | $1,138,000 | -39.1% | 107,381 | -27.7% | 0.00% | -40.0% |
| Q4 2020 | $1,870,000 | +161.5% | 148,443 | +82.4% | 0.01% | +66.7% |
| Q3 2020 | $715,000 | -5.9% | 81,365 | +3.9% | 0.00% | -25.0% |
| Q2 2020 | $760,000 | – | 78,299 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Decheng Capital Management III (Cayman), LLC | 6,708,288 | $76,809,898 | 25.63% |
| Lynx1 Capital Management LP | 2,404,614 | $27,532,830 | 18.21% |
| GREAT POINT PARTNERS LLC | 3,078,633 | $35,250,348 | 6.42% |
| Ghost Tree Capital, LLC | 664,132 | $7,604,311 | 2.50% |
| Frazier Life Sciences Management, L.P. | 2,985,757 | $34,186,918 | 2.27% |
| Paradigm Biocapital Advisors LP | 2,421,743 | $27,728,957 | 1.88% |
| COMMODORE CAPITAL LP | 1,325,000 | $15,171,250 | 1.77% |
| Nan Fung Group Holdings Ltd | 182,280 | $2,087,106 | 1.69% |
| Omega Fund Management, LLC | 153,700 | $1,759,865 | 1.62% |
| Octagon Capital Advisors LP | 750,000 | $8,587,500 | 1.32% |